Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: A trigger for pathological gambling in parkinson's disease

Neuropsychopharmacology

Volumn 34, Issue 13, 2009, Pages 2758-2766

  Van Eimeren, Thilo ^a,b   Ballanger, Bénédicte ^a,b   Pellecchia, Giovanna ^a,b   Miyasaki, Janis M ^a   Lang, Anthony E ^a   Strafella, Antonio P ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Addiction; Dopamine agonist; FMRI; Impulse control disorder; Reinforcement; Reward

Indexed keywords

BENSERAZIDE; DOPAMINE RECEPTOR; LEVODOPA; PRAMIPEXOLE;

ADULT; ARTICLE; BRAIN DEPTH STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DESENSITIZATION; DRUG WITHDRAWAL; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MALE; NEGATIVE FEEDBACK; ORBITAL CORTEX; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PREDICTION; PRIORITY JOURNAL;

BENZOTHIAZOLES; DOPAMINE AGONISTS; FRONTAL LOBE; GAMBLING; HUMANS; LEVODOPA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PARKINSON DISEASE; PSYCHOMOTOR PERFORMANCE; REWARD; RISK-TAKING;

EID: 70449380362     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2009.124     Document Type: Article

References (48)

1. Ahmed SH, Kenny PJ, Koob GF, Markou A (2002). Neurobiological evidence for hedonic allostasis associated with escalating cocaine use. Nat Neurosci 5: 625-626.
2. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association: Washington, DC; 19-94.
3. Bayer HM, Lau B, Glimcher PW (2007). Statistics of midbrain dopamine neuron spike trains in the awake primate. J Neurophysiol 98: 1428-1439.
4. Breiter HC, Aharon I, Kahneman D, Dale A, Shizgal P (2001). Functional imaging of neural responses to expectancy and experience of monetary gains and losses. Neuron 30: 619-639.
5. Cilia R, Siri C, Marotta G, Isaias IU, De Gaspari D, Canesi M et al (2008). Functional abnormalities underlying pathological gambling in Parkinson disease. Arch Neurol 65: 1604-1611.
6. Cools R (2006). Dopaminergic modulation of cognitive function- implications for L-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev 30: 123.
7. Cools R, Altamirano L, D'Esposito M (2006). Reversal learning in Parkinson's disease depends on medication status and outcome valence. Neuropsychologia 44: 1663-1673.
8. Cools R, Barker RA, Sahakian BJ, Robbins TW (2001). Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex 11: 1136-1143.
9. Driver-Dunckley E, Samanta J, Stacy M (2003). Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 61: 422-423.
10. Elliott R, Newman JL, Longe OA, Deakin JF (2003). Differential response patterns in the striatum and orbitofrontal cortex to financial reward in humans: a parametric functional magnetic resonance imaging study. J Neurosci 23: 303-307.
11. Frank MJ, Samanta J, Moustafa AA, Sherman SJ (2007). Hold your horses: impulsivity, deep brain stimulation, and medication in Parkinsonism. Science 318: 1309-1312.
12. Frank MJ, Seeberger LC, O'Reilly R C (2004). By carrot or by stick: cognitive reinforcement learning in Parkinsonism. Science 306: 1940-1943.
13. Friston KJ, Frith CD, Turner R, Frackowiak RS (1995). Characterizing evoked hemodynamics with fMRI. Neuroimage 2: 157-165.
14. Galpern WR, Stacy M (2007). Management of impulse control disorders in Parkinson's disease. Curr Treat Options Neurol 9: 189-197.
15. Garavan H, Pankiewicz J, Bloom A, Cho JK, Sperry L, Ross TJ et al (2000). Cue-induced cocaine craving: neuroanatomical specificity for drug users and drug stimuli. Am J Psychiatry 157: 1789-1798.
16. Genovese CR, Lazar NA, Nichols T (2002). Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage 15: 870-878.
17. Goldstein RZ, Tomasi D, Alia-Klein N, Cottone LA, Zhang L, Telang F et al (2007). Subjective sensitivity to monetary gradients is associated with frontolimbic activation to reward in cocaine abusers. Drug Alcohol Depend 87: 233-240.
18. Grigson PS, Twining RC (2002). Cocaine-induced suppression of saccharin intake: a model of drug-induced devaluation of natural rewards. Behav Neurosci 116: 321-333.
19. Hamidovic A, Kang UJ, de Wit H (2008). Effects of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers. J Clin Psychopharmacol 28: 45-51.
20. Hollerman JR, Tremblay L, Schultz W (1998). Influence of reward expectation on behavior-related neuronal activity in primate striatum. J Neurophysiol 80: 947-963. (Pubitemid 28387672)
21. Knutson B, Fong GW, Adams CM, Varner JL, Hommer D (2001). Dissociation of reward anticipation and outcome with event-related fMRI. Neuroreport 12: 3683-3687.
22. Knutson B, Westdorp A, Kaiser E, Hommer D (2000). FMRI visualization of brain activity during a monetary incentive delay task. Neuroimage 12: 20-27.
23. Kriegeskorte N, Simmons WK, Bellgowan PS, Baker CI (2009). Circular analysis in systems neuroscience: the dangers of double dipping. Nat Neurosci 12: 535-540.
24. Lejuez CW, Read JP, Kahler CW, Richards JB, Ramsey SE, Stuart GL et al (2002). Evaluation of a behavioral measure of risk taking: the Balloon Analogue Risk Task (BART). J Exp Psychol Appl 8: 75-84.
25. O'Doherty JP, Dayan P, Friston K, Critchley H, Dolan RJ (2003). Temporal difference models and reward-related learning in the human brain. Neuron 38: 329-337.
26. Potenza MN (2008). Review. The neurobiology of pathological gambling and drug addiction: an overview and new findings. Philos Trans R Soc Lond B Biol Sci 363: 3181-3189.
27. Pontone G, Williams JR, Bassett SS, Marsh L (2006). Clinical features associated with impulse control disorders in Parkinson disease. Neurology 67: 1258-1261.
28. Ragonese P, Salemi G, Morgante L, Aridon P, Epifanio A, Buffa D et al (2003). A case-control study on cigarette, alcohol, and coffee consumption preceding Parkinson's disease. Neuroepide-miology 22: 297-304.
29. Reuter J, Raedler T, Rose M, Hand I, Glascher J, Buchel C (2005). Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci 8: 147-148.
30. Schott BH, Niehaus L, Wittmann BC, Schutze H, Seidenbecher CI, Heinze HJ et al (2007). Ageing and early-stage Parkinson's disease affect separable neural mechanisms of mesolimbic reward processing. Brain 130: 2412-2424.
31. Schultz W (2002). Getting formal with dopamine and reward. Neuron 36: 241-263.
32. Seedat S, Kesler S, Niehaus DJ, Stein DJ (2000). Pathological gambling behavior: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depress Anxiety 11: 185-186.
33. Seeman P (2007). Anti-Parkinson therapeutic potencies correlate with their affinities at dopamine D2(High) receptors. Synapse 61: 1013-1018.
34. Shohamy D, Myers CE, Grossman S, Sage J, Gluck MA, Poldrack RA (2004). Cortico-striatal contributions to feedback-based learning: converging data from neuroimaging and neuropsy-chology. Brain 127: 851-859.
35. Steeves TDL, Miyasaki J, Zurowski M, Lang AE, Pellecchia G, van Eimeren T et al (2009). Increased ventral striatal dopamine release in Parkinson's disease patients with pathological gambling: a [11C] raclopride PET study. Brain 132: 1376-1385.
36. Sutton RS, Barto AG (1998). Reinforcement Learning: An Introduction. MIT Press: Cambridge, MA; 19-98.
37. Swainson R, Rogers RD, Sahakian BJ, Summers BA, Polkey CE, Robbins TW (2000). Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. Neuropsychologia 38: 596-612.
38. Tomer R, Aharon-Peretz J (2004). Novelty seeking and harm avoidance in Parkinson's disease: effects of asymmetric dopamine deficiency. J Neurol Neurosurg Psychiatry 75: 972-975.
39. Tremblay L, Schultz W (1999). Relative reward preference in primate orbitofrontal cortex. Nature 398: 704-708.
40. Valentin VV, Dickinson A, O'Doherty JP (2007). Determining the neural substrates of goal-directed learning in the human brain. J Neurosci 27: 4019-4026.
41. Volkow ND, Fowler JS, Wang GJ (2004). The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies. Neuropharmacology 47(Suppl 1): 313.
42. Volkow ND, Fowler JS, Wang GJ, Baler R, Telang F (2009). Imaging dopamine's role in drug abuse and addiction. Neuropharmacol-ogy 56(Suppl 1): 38.
43. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Hitzemann R et al (1997). Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 386: 830-833.
44. Voon V, Hassan K, Zurowski M, Duff-Canning S, de Souza M, Fox S et al (2006). Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 66: 1750-1752.
45. Waelti P, Dickinson A, Schultz W (2001). Dopamine responses comply with basic assumptions of formal learning theory. Nature 412: 43-48.
46. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy MA, Whetteckey J et al (2008), for the DOMINION Study Group. Domapinergic Therapy and Impulse Control Disorders in Parkinson's Diesease: Top Line Results of a Cross-Sectional Study of Over 3,000 Patients. 12th International Congress of Parkinson's Disease and Movement Disorders: Chicago, IL; 20-108
47. White TL, Lejuez CW, de Wit H (2008). Test-retest characteristics of the Balloon Analogue Risk Task (BART). Exp Clin Psycho-pharmacol 16: 565-570.
48. Yacubian J, Glascher J, Schroeder K, Sommer T, Braus DF, Buchel C (2006). Dissociable systems for gain-and loss-related value predictions and errors of prediction in the human brain. J Neurosci 26: 9530-9537.